Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07760506

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.

The main questions it aims to answer are:

1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo? 2. What side effects, if any, do participants have while taking these supplements?

Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient).

Participants will:

1. Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks 2. Go to a preferred clinic at the start and end of the study for a fasting blood draw

Complete at-home tests: 3. Grip strength testing (using a device mailed to them) 4. Online surveys about fatigue and quality of life 5. Report any side effects and keep track of supplement use

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Healthy Aging Coenzyme Q10 Glucose Intolerance Glucose Metabolism Disorders Hyperglycemia Inflammaging Metabolic Diseases Metabolic Health Nutritional and Metabolic Diseases Quercetin

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study will be a randomized, double-blind, placebo-controlled clinical study conducted over a 12-week intervention investigating the effects of Quercefit® (500 mg daily, 250 mg twice daily), Ubiqsome™ (300 mg daily, 150 mg twice daily), or a placebo (twice daily). Participants will be recruited nationally in a decentralized format and will complete testing procedures remotely, with blood draws conducted through partner labs and electronic survey assessments. Key biomarkers of inflammaging, phenotypic aging, biological age, glucose regulation, insulin sensitivity, insulin resistance, lipid profile, and cardiovascular health will be examined through repeated assessments as described below.

This study will enroll 60 sedentary men and women, selected based on the inclusion and exclusion criteria defined in the protocol. Only individuals who meet all inclusion criteria and none of the exclusion criteria will be considered eligible. Recruitment will occur through an online participant database, through which applicants will be sent initial subject material. To begin enrollment, participants will complete screening to verify they are clinically overweight to obese (BMI ≥ 25.00 kg/m²), are sedentary men and women aged 50 to 75 years old, and are free of chronic cardiovascular, neurological, hepatic, renal, or metabolic disease, as determined by a health history questionnaire. As part of the screening process, participants will also be required to score 5 or higher on the CDC's prediabetes risk test (https://www.cdc.gov/prediabetes/takethetest). Finally, participants must not currently be using glucose-lowering agents or insulin.

Upon passing all inclusion and exclusion criteria, participants will confirm their address and general availability. Before any study-related procedures are completed, participants will be asked to review and sign an informed consent form. Afterward, participants will be assigned a designated requisition form for blood collection at their preferred Labcorp location. During week one of testing, after a minimum 10-hour overnight fast from food, participants will arrive at the preferred Labcorp location confirmed during enrollment and complete a venipuncture-based blood draw for the collection of fasting biomarkers. This panel will include markers used to calculate composite inflammaging burden (CIMKDM), phenotypic age, metabolic health (glucose, insulin, HbA1c, HOMA-IR, QUICKI), lipid and cardiovascular risk factors, organ function (liver, kidney), inflammatory mediators (CRP, cortisol), and complete blood count with differential. Lab results will be emailed to research staff approximately 3 to 5 business days post-collection.

On a separate day that same week, participants will complete physical and subjective testing remotely, including: (1) a grip strength assessment, conducted in triplicate on both hands using a digital hand dynamometer provided by the study team, and (2) completion of an electronic questionnaire including the Modified Fatigue Impact Scale (MFIS-21) and the Short Form-36 (SF-36) Health Survey. Instructions for standardized handgrip testing and survey completion will be provided electronically upon enrollment to the participant's email.

Following completion of baseline assessments, participants will begin daily supplementation of their prescribed study materials with their assigned treatment group: Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), or placebo, taken as one capsule in the morning and one capsule in the evening, for a total of two capsules daily over 12 weeks. Participants will be instructed to maintain consistent dosing of the supplement with water and will log compliance and adverse events routinely. Check-ins will occur at baseline, week 12, and periodically in between to monitor adherence and assess for adverse events.

On days 84 through 90 post-initial treatment, all baseline measures will be repeated following the same structure: a blood draw following an overnight fast, coordinated with the participant's preferred lab partner, followed that same week by remote grip strength testing and completion of the electronic questionnaires. Final adverse event assessments and compliance documentation will also be collected at this time. All procedures are designed to be completed remotely with direct coordination from study staff. Participants will be instructed to report any adverse events immediately and will receive regular contact throughout the study to support protocol adherence and data quality.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females aged 50 to 75 years
  • Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).
  • BMI of > or equal to 25.00kg/m²
  • Individuals with > or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
  • Free of all other chronic diseases.
  • Not currently using glucose-lowering agents or insulin.
  • Able to read and write in English
  • Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.
  • During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.
  • During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements
  • Willing to have blood drawn
  • Must have access to a reliable internet connection and a computer to complete remote assessments

Exclusion criteria

  • Unwilling to have blood drawn
  • Unwilling to swallow pills
  • Pregnancy or has breast fed within 3 months prior to enrollment
  • Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months
  • Current use of Quercetine or CoQ10 supplements within the past 4-weeks
  • History or current alcohol or drug abuse
  • Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.
  • Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B/C, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment
  • Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
  • History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)
  • History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)
  • History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)
  • History of kidney or liver disease
  • History of metabolic disorders (diabetes, metabolic syndrome, other)
  • History of current malignancy/cancer
  • Receiving chemotherapy agents or radiation treatments
  • Diagnosis of a terminal illness
  • The investigator feels that, for any reason, the subject is not eligible to participate in the study

Treatment and study plan

Quercetin (dietary supplement)

Dietary Supplement

Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.

Coenzyme Q10

Dietary Supplement

Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.

Rice flour

Dietary Supplement

An inert carbohydrate used as the control treatment

Primary outcomes

  1. Inflammaging (CIMKDM)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory using standardized assay protocols. Inflammaging (CIMKDM) is a biologically derived estimate of age, expressed in years, calculated from a composite of inflammatory biomarkers reflecting chronic low-grade inflammation and immune system activation. Higher values indicate a greater degree of inflammation-related biological aging.

  2. Phenotypic Age

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory. Phenotypic Age is a composite biomarker-based estimate of biological aging, expressed in years, derived from chronological age and nine clinical chemistry and hematological markers (albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count). Higher values relative to chronological age indicate accelerated biological aging.

Secondary outcomes

  1. Grip Strength

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Handgrip strength will be assessed remotely using a digital hand dynamometer provided by the study team. Participants will perform three maximal isometric contractions on each hand, following standardized instructions for hand positioning and testing technique provided electronically at enrollment. The highest recorded value, in kilograms of force, will be used for analysis. This assessment serves as a practical indicator of overall muscle function and physical health.

  2. Insulin Resistance (HOMA-IR)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Calculated from fasting glucose and fasting insulin values obtained via venipuncture blood draw at a Labcorp location following a minimum 10-hour overnight fast, using the standard HOMA-IR formula. Higher scores indicate greater insulin resistance.

  3. Insulin Sensitivity (QUICKI)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Calculated from fasting glucose and fasting insulin values obtained via venipuncture blood draw at a Labcorp location following a minimum 10-hour overnight fast, using the standard QUICKI formula. Values typically range from approximately 0.3 to 0.4; higher values indicate better insulin sensitivity.

  4. High-Sensitivity C-Reactive Protein (hs-CRP)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory. hs-CRP is a marker of systemic inflammation, reported in mg/L. Higher values indicate greater inflammation.

  5. Cortisol

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory. Cortisol serves as a marker of stress hormone status, reported in mcg/dL.

  6. Lipid and Cardiovascular Risk Panel

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    A fasting venous blood sample will be collected via venipuncture at a Labcorp location following a minimum 10-hour overnight fast and processed at a central laboratory. The panel includes total cholesterol (mg/dL), triglycerides (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), VLDL cholesterol (mg/dL), and the total cholesterol/HDL ratio (a calculated, unitless ratio). Together, these values are used to assess cardiovascular risk and complement biological age estimates.

  7. Uric Acid

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.

  8. Blood Urea Nitrogen (BUN)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.

  9. Creatinine

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.

  10. BUN/Creatinine Ratio

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Calculated from BUN and creatinine values obtained via the kidney function panel from a fasting venous blood sample. A calculated, unitless ratio used to assess kidney function.

  11. Fatigue Impact (Modified Fatigue Impact Scale, MFIS-21)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Participants will complete the MFIS-21 electronically via a secure survey link provided at enrollment. The MFIS-21 is a 21-item self-report scale assessing the impact of fatigue on physical, cognitive, and psychosocial functioning. Each item is rated on a 5-point scale ranging from 0 ("never") to 4 ("almost always"). Item scores are summed to produce a total score ranging from 0 to 84. Higher total scores indicate greater fatigue impact (worse outcome).

  12. Health-Related Quality of Life (Short Form-36, SF-36)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Participants will complete the SF-36 electronically via a secure survey link provided at enrollment. The SF-36 assesses health-related quality of life across 8 domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Question responses range from 1 to 5 or 1 to 6 depending on the item, and each domain's responses are converted to a score from 0 to 100. For all domains, higher scores indicate greater well-being.

  13. Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Calculated from serum creatinine, age, and sex using a standard eGFR equation applied by the central laboratory. Reported in mL/min/1.73m².

  14. Sodium

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.

  15. Potassium

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.

  16. Chloride

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.

  17. Calcium

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mg/dL.

  18. Phosphorus

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mg/dL.

  19. Iron

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mcg/dL.

  20. Total Protein

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in g/dL.

  21. Albumin

    Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in g/dL.

  22. Bilirubin (Total)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in mg/dL.

  23. Alanine Aminotransferase (ALT)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.

  24. Aspartate Aminotransferase (AST)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.

  25. Alkaline Phosphatase (ALP)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.

  26. Red Blood Cell Count (RBC)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in million cells/µL.

  27. Hemoglobin

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in g/dL.

  28. Hematocrit

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported as a percentage.

  29. Mean Corpuscular Volume (MCV)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in fL.

  30. Mean Corpuscular Hemoglobin (MCH)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in pg.

  31. Mean Corpuscular Hemoglobin Concentration (MCHC)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in g/dL.

  32. Red Cell Distribution Width (RDW)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported as a percentage.

  33. White Blood Cell Count with Differential (WBC)

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in thousand cells/µL.

  34. Platelet Count

    Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)

    Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in thousand cells/µL.

  35. Adverse events (AE)

    Time frame: Time Frame: Baseline (Week 1) through Post-Intervention (Day 84 to 90)

    Adverse events will be monitored continuously throughout the 12-week intervention via structured AE queries conducted by study staff through phone or secure digital check-in, in addition to participant self-report. All AEs will be documented and assessed for severity and relationship to the study product by the investigator.

Study contacts

Contact information is provided by the study sponsor or research team.

Gabe Wilson, PhD

CONTACT

[email protected]

8136738888

Tony Zavala, BS

CONTACT

[email protected]

8138678888

Sponsors and collaborators

Lead sponsor

Applied Science & Performance Institute

Industry

Registry information

Official study title

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 12, 2026
Registry last updated
Aug 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.